Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Naldemedine | Experimental | Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks. |
|
| Placebo | Placebo Comparator | Participants received matching placebo tablets orally once daily for 52 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Naldemedine | Drug | Naldemedine 0.2 mg tablet taken orally once a day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Events | A serious adverse event was defined as any adverse event (AE) that resulted in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life threatening, or require hospitalization were considered an SAE when, based upon appropriate medical judgment, they jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. Adverse drug reactions (ADRs) were defined as adverse events that were considered by the investigator to be definitely, probably, or possibly related to study drug. Serious ADRs were defined as serious AEs considered by the investigator to be definitely, probably, or possibly related to study drug. | From the first dose of study drug up to 14 days after the last dose of study drug (54 weeks). |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the Number of Bowel Movements Per Week | Participants monitored their bowel movements and completed a daily bowel habits diary the week prior to study visits (i.e. during Weeks 11, 23, 35, and 51). | Baseline and Weeks 12, 24, 36, and 52 |
| Percentage of Participants Meeting Each Criterion of Laxative Use |
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shionogi Clinical Trials Administrator Clinical Support Help Line | Shionogi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shionogi Research Site | Birmingham | Alabama | United States | |||
| Shionogi Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34295186 | Derived | Camilleri M, Hale M, Morlion B, Tack J, Webster L, Wild J. Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies. J Pain Res. 2021 Jul 16;14:2179-2189. doi: 10.2147/JPR.S282738. eCollection 2021. | |
| 32280263 | Derived |
Not provided
Not provided
Participants were randomized in a 1:1 ratio to receive naldemedine or placebo for 52 weeks. Randomization was stratified based on documented opioid use (average total daily dose [TDD] during the 14-consecutive-day qualifying period) as follows:
This study was conducted at 195 clinical sites in North America (Canada and the United States), Europe (Belgium, Denmark, Estonia, France, Germany, Hungary, Poland, Spain, Sweden, and the United Kingdom), and Africa/Asia Pacific (Australia and South Africa)
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Naldemedine | Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks. |
| FG001 | Placebo | Participants received placebo tablets orally once daily for 52 weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo tablet taken orally once a day |
|
Participants who were taking stable routine/regular laxatives at Screening were to continue taking the same regimen throughout the study. The percentage of participants meeting each of the criteria below are reported: 1. Participants not on stable laxatives, defined as participants who did not use laxatives from 28 days prior to the Screening Period to the final dose of study drug or who received only rescue laxative. Rescue is defined as any laxative taken for the first time during the Treatment Period. 1a. Out of participants who were not on stable laxatives, participants who received rescue laxatives. 2. Participants on stable laxatives, defined as participants who may have had at least one/any stable laxative use reported from 28 days prior to Screening Period to the final dose of study drug. 2a. Out of participants who were on stable laxatives, participants who received rescue laxatives. 3. Participants who did not meet criteria 1 or 2. |
| From 28 days prior to screening until the end of the treatment period (total of 56 weeks) |
| Change From Baseline in the Overall Score for Patient Assessment of Constipation Symptoms | The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The overall score was calculated as the mean of all 12 items and ranges from 0 (best) to 4 (worst). A negative change from baseline value indicates improvement. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Change From Baseline in the PAC-SYM Abdominal-symptoms Domain Score | The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The abdominal-symptom domain score was calculated as the mean of the following 4 items: abdominal discomfort, abdominal pain, abdominal bloating and stomach cramps. A negative change from baseline value indicates improvement in symptoms. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Change From Baseline in the PAC-SYM Rectal-symptoms Domain Score | The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The abdominal-symptom domain score was calculated as the mean of the following 3 items: painful bowel movements, rectal burning during or after a bowel movement, and rectal bleeding or tearing during or after a bowel movement. A negative change from baseline value indicates improvement in symptoms. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Change From Baseline in the PAC-SYM Stool-symptoms Domain Score | The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The stool-symptom domain score was calculated as the mean of the following 5 items: incomplete bowel movements, bowel movements that were too hard, bowel movements that were too small, straining or squeezing to try to pass bowel movements, and false-alarm bowel movements. A negative change from baseline value indicates improvement in symptoms. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Change From Baseline in the Patient Assessment of Constipation Quality of Life Overall Score | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The overall score was calculated as the mean of all 28 item scores. A negative change from baseline value indicates improvement. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Change From Baseline in the Physical Discomfort Domain of PAC-QOL | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The physical discomfort domain consists of 4 questions related to bloating, feeling heavy, how much of the time participants felt any physical discomfort and how much time they felt the need to open their bowel but were not able to. The physical discomfort score was calculated as the mean of the 4 individual scores. A negative change from baseline value indicates improvement. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Change From Baseline in the Psychosocial Discomfort Domain of PAC-QOL | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The psychosocial discomfort domain consists of 8 questions related to participants' embarrassment regarding their constipation and effects of constipation on eating habits and appetite. The psychosocial discomfort score was calculated as the mean of the 8 individual scores. A negative change from baseline value indicates improvement. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Change From Baseline in the Worries and Concerns Domain of PAC-QOL | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The worries and concerns domain consists of 11 questions related to participants' feelings and concerns about their constipation. The worries and concerns domain score was calculated as the mean of the 11 individual scores. A negative change from baseline value indicates improvement. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Change From Baseline in the Satisfaction Domain of PAC-QOL | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The satisfaction domain consists of 5 questions related to participants' feelings of satisfaction with their bowel function. The satisfaction domain score was calculated as the mean of the 5 individual scores. A negative change from baseline value indicates improvement. | Baseline and Weeks 2, 12, 24, 36, and 52 |
| Participant Global Satisfaction | Participants were asked to rate their degree of satisfaction of constipation and abdominal symptoms from the start of study drug dosing to Week 52 (or early termination). Satisfaction was rated based on the following seven grades:
| Week 52 or early termination visit |
| Mobile |
| Alabama |
| United States |
| Shionogi Research Site | Chandler | Arizona | United States |
| Shionogi Research Site | Glendale | Arizona | United States |
| Shionogi Research Site | Goodyear | Arizona | United States |
| Shionogi Research Site | Mesa | Arizona | United States |
| Shionogi Research Site | Phoenix | Arizona | United States |
| Shionogi Research Site | Tucson | Arizona | United States |
| Shionogi Research Site | Fountain Valley | California | United States |
| Shionogi Research Site | Garden Grove | California | United States |
| Shionogi Research Site | Glendale | California | United States |
| Shionogi Research Site | Long Beach | California | United States |
| Shionogi Research Site | Los Angeles | California | United States |
| Shionogi Research Site | Oceanside | California | United States |
| Shionogi Research Site | Sacramento | California | United States |
| Shionogi Research Site | Santa Ana | California | United States |
| Shionogi Research Site | Upland | California | United States |
| Shionogi Research Site | Colorado Springs | Colorado | United States |
| Shionogi Research Site | Boynton Beach | Florida | United States |
| Shionogi Research Site | Brandon | Florida | United States |
| Shionogi Research Site | Brooksville | Florida | United States |
| Shionogi Research Site | Clearwater | Florida | United States |
| Shionogi Research Site | Fort Myers | Florida | United States |
| Shionogi Research Site | Jacksonville | Florida | United States |
| Shionogi Research Site | Lake City | Florida | United States |
| Shionogi Research Site | Lakeland | Florida | United States |
| Shionogi Research Site | Orlando | Florida | United States |
| Shionogi Research Site | South Miami | Florida | United States |
| Shionogi Research Site | St. Petersburg | Florida | United States |
| Shionogi Research Site | Tampa | Florida | United States |
| Shionogi Research Site | Atlanta | Georgia | United States |
| Shionogi Research Site | Blue Ridge | Georgia | United States |
| Shionogi Research Site | Decatur | Georgia | United States |
| Shionogi Research Site | Savannah | Georgia | United States |
| Shionogi Research Site | Boise | Idaho | United States |
| Shionogi Research Site | Aurora | Illinois | United States |
| Shionogi Research Site | Bloomington | Illinois | United States |
| Shionogi Research Site | Decatur | Illinois | United States |
| Shionogi Research Site | Rockford | Illinois | United States |
| Shionogi Research Site | Schaumburg | Illinois | United States |
| Shionogi Research Site | Evansville | Indiana | United States |
| Shionogi Research Site | Lafayette | Indiana | United States |
| Shionogi Research Site | Valparaiso | Indiana | United States |
| Shionogi Research Site | Augusta | Kansas | United States |
| Shionogi Research Site | Newton | Kansas | United States |
| Shionogi Research Site | Wichita | Kansas | United States |
| Shionogi Research Site | Hartford | Kentucky | United States |
| Shionogi Research Site | Eunice | Louisiana | United States |
| Shionogi Research Site | Lake Charles | Louisiana | United States |
| Shionogi Research Site | Mandeville | Louisiana | United States |
| Shionogi Research Site | Brockton | Massachusetts | United States |
| Shionogi Research Site | Fall River | Massachusetts | United States |
| Shionogi Research Site | New Bedford | Massachusetts | United States |
| Shionogi Research Site | Rochester | Michigan | United States |
| Shionogi Research Site | Saginaw | Michigan | United States |
| Shionogi Research Site | Traverse City | Michigan | United States |
| Shionogi Research Site | Biloxi | Mississippi | United States |
| Shionogi Research Site | Fremont | Nebraska | United States |
| Shionogi Research Site | Omaha | Nebraska | United States |
| Shionogi Research Site | Henderson | Nevada | United States |
| Shionogi Research Site | Las Vegas | Nevada | United States |
| Shionogi Research Site | Trenton | New Jersey | United States |
| Shionogi Research Site | Albuquerque | New Mexico | United States |
| Shionogi Research Site | New York | New York | United States |
| Shionogi Research Site | Greensboro | North Carolina | United States |
| Shionogi Research Site | Wilmington | North Carolina | United States |
| Shionogi Research Site | Winston-Salem | North Carolina | United States |
| Shionogi Research Site | Akron | Ohio | United States |
| Shionogi Research Site | Canton | Ohio | United States |
| Shionogi Research Site | Columbus | Ohio | United States |
| Shionogi Research Site | Groveport | Ohio | United States |
| Shionogi Research Site | Kettering | Ohio | United States |
| Shionogi Research Site | Lebanon | Ohio | United States |
| Shionogi Research Site | Marion | Ohio | United States |
| Shionogi Research Site | Munroe Falls | Ohio | United States |
| Shionogi Research Site | Oklahoma City | Oklahoma | United States |
| Shionogi Research Site | Tulsa | Oklahoma | United States |
| Shionogi Research Site | Portland | Oregon | United States |
| Shionogi Research Site | Huntingdon Valley | Pennsylvania | United States |
| Shionogi Research Site | Jenkintown | Pennsylvania | United States |
| Shionogi Research Site | Lansdale | Pennsylvania | United States |
| Shionogi Research Site | Charleston | South Carolina | United States |
| Shionogi Research Site | Greer | South Carolina | United States |
| Shionogi Research Site | Myrtle Beach | South Carolina | United States |
| Shionogi Research Site | Summerville | South Carolina | United States |
| Shionogi Research Site | Bristol | Tennessee | United States |
| Shionogi Research Site | Milan | Tennessee | United States |
| Shionogi Research Site | Nashville | Tennessee | United States |
| Shionogi Research Site | Austin | Texas | United States |
| Shionogi Research Site | Dallas | Texas | United States |
| Shionogi Research Site | Houston | Texas | United States |
| Shionogi Research Site | Hurst | Texas | United States |
| Shionogi Research Site | Sugar Land | Texas | United States |
| Shionogi Research Site | Bountiful | Utah | United States |
| Shionogi Research Site | Salt Lake City | Utah | United States |
| Shionogi Research Site | South Ogden | Utah | United States |
| Shionogi Research Site | Richmond | Virginia | United States |
| Shionogi Research Site | Bellevue | Washington | United States |
| Shionogi Research Site | Edmonds | Washington | United States |
| Shionogi Research Site | Adelaide | Australia |
| Shionogi Research Site | Bedford Park | Australia |
| Shionogi Research Site | Camperdown | Australia |
| Shionogi Research Site | Carina Heights | Australia |
| Shionogi Research Site | Caulfield South | Australia |
| Shionogi Research Site | Malvern East | Australia |
| Shionogi Research Site | Nambour | Australia |
| Shionogi Research Site | Sherwood | Australia |
| Shionogi Research Site | St Leonards | Australia |
| Shionogi Research Site | Linz | Austria |
| Shionogi Research Site | Vienna | Austria |
| Shionogi Research Site | Zams | Austria |
| Shionogi Research Site | London | Canada |
| Shionogi Research Site | Mirabel | Canada |
| Shionogi Research Site | Sarnia | Canada |
| Shionogi Research Site | Sherbrooke | Canada |
| Shionogi Research Site | Toronto | Canada |
| Shionogi Research Site | Vancouver | Canada |
| Shionogi Research Site | Benešov | Czechia |
| Shionogi Research Site | Olomouc | Czechia |
| Shionogi Research Site | Ostrava | Czechia |
| Shionogi Research Site | Pardubice | Czechia |
| Shionogi Research Site | Pribram V- Zdabor | Czechia |
| Shionogi Research Site | Glostrup Municipality | Denmark |
| Shionogi Research Site | Hellerup | Denmark |
| Shionogi Research Site | Odense | Denmark |
| Shionogi Research Site | Soulaine Sur Aubance | France |
| Shionogi Research Site | Berlin | Germany |
| Shionogi Research Site | Dresden | Germany |
| Shionogi Research Site | Halle | Germany |
| Shionogi Research Site | Hamburg | Germany |
| Shionogi Research Site | Hanover | Germany |
| Shionogi Research Site | Kassel | Germany |
| Shionogi Research Site | Leipzig | Germany |
| Shionogi Research Site | Lünen | Germany |
| Shionogi Research Site | Mainz | Germany |
| Shionogi Research Site | Münster | Germany |
| Shionogi Research Site | Stadtroda | Germany |
| Shionogi Research Site | Balatonfüred | Hungary |
| Shionogi Research Site | Budapest | Hungary |
| Shionogi Research Site | Debrecen | Hungary |
| Shionogi Research Site | Hatvan | Hungary |
| Shionogi Research Site | Szikszó | Hungary |
| Shionogi Research Site | Beersheba | Israel |
| Shionogi Research Site | Haifa | Israel |
| Shionogi Research Site | Tel Aviv | Israel |
| Shionogi Research Site | Tel Litwinsky | Israel |
| Shionogi Research Site | Asti | Italy |
| Shionogi Research Site | Catania | Italy |
| Shionogi Research Site | Chieti | Italy |
| Shionogi Research Site | Florence | Italy |
| Shionogi Research Site | Naples | Italy |
| Shionogi Research Site | Rionero in Vulture | Italy |
| Shionogi Research Site | Roma | Italy |
| Shionogi Research Site | Rome | Italy |
| Shionogi Research Site | Chorzów | Poland |
| Shionogi Research Site | Gdansk | Poland |
| Shionogi Research Site | Katowice | Poland |
| Shionogi Research Site | Lublin | Poland |
| Shionogi Research Site | Alberton | South Africa |
| Shionogi Research Site | Lyttelton Centurion | South Africa |
| Shionogi Research Site | Muckleneuk Pretoria | South Africa |
| Shionogi Research Site | Pretoria West Pretoria | South Africa |
| Shionogi Research Site | Worcester | South Africa |
| Shionogi Research Site | Barcelona | Spain |
| Shionogi Research Site | Girona | Spain |
| Shionogi Research Site | Seville | Spain |
| Shionogi Research Site | Skene | Sweden |
| Shionogi Research Site | Stockholm | Sweden |
| Shionogi Research Site | Bath | United Kingdom |
| Shionogi Research Site | Belfast | United Kingdom |
| Shionogi Research Site | Bexhill on Sea East Sussex | United Kingdom |
| Shionogi Research Site | Chesterfield | United Kingdom |
| Shionogi Research Site | Chestfield Kent | United Kingdom |
| Shionogi Research Site | Daventry Northants | United Kingdom |
| Shionogi Research Site | Devon | United Kingdom |
| Shionogi Research Site | Epworth Doncaster | United Kingdom |
| Shionogi Research Site | Harrogate | United Kingdom |
| Shionogi Research Site | Hinckley | United Kingdom |
| Shionogi Research Site | Liverpool | United Kingdom |
| Shionogi Research Site | Norwich | United Kingdom |
| Shionogi Research Site | Oldham | United Kingdom |
| Shionogi Research Site | Peterborough | United Kingdom |
| Shionogi Research Site | Randalstown, County Antrim | United Kingdom |
| Shionogi Research Site | Spiro Close, Pulborough West Sussex | United Kingdom |
| Shionogi Research Site | Wellingborough Northamptonshire | United Kingdom |
| Shionogi Research Site | York | United Kingdom |
| Webster LR, Hale ME, Yamada T, Wild JE. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy. J Pain Res. 2020 Mar 24;13:605-612. doi: 10.2147/JPR.S237833. eCollection 2020. |
| 32086791 | Derived | Wild J, Webster L, Yamada T, Hale M. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients >/= 65 Years of Age. Drugs Aging. 2020 Apr;37(4):271-279. doi: 10.1007/s40266-020-00753-2. |
| Received Treatment |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
The safety population included all participants who received at least 1 dose of study drug. Five participants (2 in the naldemedine group and 3 in the placebo group) were excluded due to double enrollment at different sites. One participant in the placebo arm received naldemedine in error and is included in the naldemedine arm for safety analyses.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Naldemedine | Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks. |
| BG001 | Placebo | Participants received placebo tablets orally once daily for 52 weeks. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Age, Customized | Number | participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
| ||||||||||||||||
| Stratification by Opioid Dose | Dose of opioid was calculated using maintenance and breakthrough morphine equivalent dose. If any participants were treated with < 30 mg, the participants were counted in the '30-100' group. | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Adverse Events | A serious adverse event was defined as any adverse event (AE) that resulted in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life threatening, or require hospitalization were considered an SAE when, based upon appropriate medical judgment, they jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. Adverse drug reactions (ADRs) were defined as adverse events that were considered by the investigator to be definitely, probably, or possibly related to study drug. Serious ADRs were defined as serious AEs considered by the investigator to be definitely, probably, or possibly related to study drug. | Safety population | Posted | Number | participants | From the first dose of study drug up to 14 days after the last dose of study drug (54 weeks). |
|
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Number of Bowel Movements Per Week | Participants monitored their bowel movements and completed a daily bowel habits diary the week prior to study visits (i.e. during Weeks 11, 23, 35, and 51). | The intent-to-treat population includes all randomized participants. Five participants were excluded due to double enrollment at different sites. | Posted | Least Squares Mean | Standard Error | bowel movements / week | Baseline and Weeks 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Meeting Each Criterion of Laxative Use | Participants who were taking stable routine/regular laxatives at Screening were to continue taking the same regimen throughout the study. The percentage of participants meeting each of the criteria below are reported: 1. Participants not on stable laxatives, defined as participants who did not use laxatives from 28 days prior to the Screening Period to the final dose of study drug or who received only rescue laxative. Rescue is defined as any laxative taken for the first time during the Treatment Period. 1a. Out of participants who were not on stable laxatives, participants who received rescue laxatives. 2. Participants on stable laxatives, defined as participants who may have had at least one/any stable laxative use reported from 28 days prior to Screening Period to the final dose of study drug. 2a. Out of participants who were on stable laxatives, participants who received rescue laxatives. 3. Participants who did not meet criteria 1 or 2. | Intent-to-treat population | Posted | Number | percentage of participants | From 28 days prior to screening until the end of the treatment period (total of 56 weeks) |
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Overall Score for Patient Assessment of Constipation Symptoms | The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The overall score was calculated as the mean of all 12 items and ranges from 0 (best) to 4 (worst). A negative change from baseline value indicates improvement. | The intent-to-treat population includes all randomized participants. Five participants were excluded due to double enrollment at different sites. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the PAC-SYM Abdominal-symptoms Domain Score | The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The abdominal-symptom domain score was calculated as the mean of the following 4 items: abdominal discomfort, abdominal pain, abdominal bloating and stomach cramps. A negative change from baseline value indicates improvement in symptoms. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the PAC-SYM Rectal-symptoms Domain Score | The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The abdominal-symptom domain score was calculated as the mean of the following 3 items: painful bowel movements, rectal burning during or after a bowel movement, and rectal bleeding or tearing during or after a bowel movement. A negative change from baseline value indicates improvement in symptoms. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the PAC-SYM Stool-symptoms Domain Score | The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) asked participants to rate the severity of 12 constipation symptoms in the last 2 weeks on a scale from 0 (absent) to 4 (very severe). The stool-symptom domain score was calculated as the mean of the following 5 items: incomplete bowel movements, bowel movements that were too hard, bowel movements that were too small, straining or squeezing to try to pass bowel movements, and false-alarm bowel movements. A negative change from baseline value indicates improvement in symptoms. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Patient Assessment of Constipation Quality of Life Overall Score | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The overall score was calculated as the mean of all 28 item scores. A negative change from baseline value indicates improvement. | Intent-to-treat | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Physical Discomfort Domain of PAC-QOL | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The physical discomfort domain consists of 4 questions related to bloating, feeling heavy, how much of the time participants felt any physical discomfort and how much time they felt the need to open their bowel but were not able to. The physical discomfort score was calculated as the mean of the 4 individual scores. A negative change from baseline value indicates improvement. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Psychosocial Discomfort Domain of PAC-QOL | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The psychosocial discomfort domain consists of 8 questions related to participants' embarrassment regarding their constipation and effects of constipation on eating habits and appetite. The psychosocial discomfort score was calculated as the mean of the 8 individual scores. A negative change from baseline value indicates improvement. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Worries and Concerns Domain of PAC-QOL | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The worries and concerns domain consists of 11 questions related to participants' feelings and concerns about their constipation. The worries and concerns domain score was calculated as the mean of the 11 individual scores. A negative change from baseline value indicates improvement. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in the Satisfaction Domain of PAC-QOL | The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) consists of 28 questions designed to measure the impact constipation has had on participants' daily life during the past 2 weeks. Each question was evaluated by the participant on a five-point scale ranging from 0 (not at all or none of the time) to 4 (extremely or all of the time), where higher scores represent poorer quality of life. The satisfaction domain consists of 5 questions related to participants' feelings of satisfaction with their bowel function. The satisfaction domain score was calculated as the mean of the 5 individual scores. A negative change from baseline value indicates improvement. | Intent-to-treat population | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline and Weeks 2, 12, 24, 36, and 52 |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Participant Global Satisfaction | Participants were asked to rate their degree of satisfaction of constipation and abdominal symptoms from the start of study drug dosing to Week 52 (or early termination). Satisfaction was rated based on the following seven grades:
| Intent-to-treat population | Posted | Number | percentage of participants | Week 52 or early termination visit |
|
|
From the first dose of study drug up to 14 days after the last dose of study drug (54 weeks).
The safety population included all participants who were randomized and received at least 1 dose of study drug and were analyzed by the treatment actually received. Five participants (2 in the naldemedine group and 3 in the placebo group) were excluded due to double enrollment at different sites. One participant in the placebo arm received naldemedine in error and is included in the naldemedine arm for safety analyses.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Naldemedine | Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks. | 60 | 621 | 225 | 621 | ||
| EG001 | Placebo | Participants received placebo tablets orally once daily for 52 weeks. | 73 | 619 | 179 | 619 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Appendicitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Arthritis Bacterial | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Cellulitis Orbital | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Incision Site Infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Infected Skin Ulcer | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Lobar Pneumonia | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Localised Infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Necrotising Fasciitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Otitis Media | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Parotitis | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Pneumonia Bacterial | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Post Procedural Infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Subcutaneous Abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Tooth Abscess | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Tooth Infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Urinary Tract Infection Pseudomonal | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Urosepsis | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Viral Infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment |
| |
| Adenocarcinoma of Colon | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment |
| |
| Bladder Transitional Cell Carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment |
| |
| Breast Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment |
| |
| Lung Adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment |
| |
| Small Cell Lung Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment |
| |
| Squamous Cell Carcinoma of Lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 16.0 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Acute Psychosis | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Confusional State | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Mental Status Changes | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Panic Attack | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Psychotic Disorder | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Stress | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Suicidal Ideation | Psychiatric disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Carotid Artery Stenosis | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Carpal Tunnel Syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Cerebrovascular Accident | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Cervicobrachial Syndrome | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Loss of Consciousness | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Metabolic Encephalopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Spinal Claudication | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Toxic Encephalopathy | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Transient Ischaemic Attack | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Acute Myocardial Infarction | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Angina Pectoris | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Angina Unstable | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Atrioventricular Block First Degree | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Cardiac Arrest | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Cardiac Failure Congestive | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Mitral Valve Incompetence | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Myocardial Infarction | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Sinus Tachycardia | Cardiac disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Arteriosclerosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Deep Vein Thrombosis | Vascular disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Femoral Artery Occlusion | Vascular disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Orthostatic Hypotension | Vascular disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Peripheral Arterial Occlusive Disease | Vascular disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Peripheral Vascular Disorder | Vascular disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Acute Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Bronchitis Chronic | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Chronic Obstructive Pulmonary Disease | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Pleurisy | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Sinus Polyp | Respiratory, thoracic and mediastinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Abdominal Pain | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Abdominal Pain Lower | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Colitis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Flatulence | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Gastric Varices | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Gastric Volvulus | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Gastritis | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Gastrooesophageal Reflux Disease | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Impaired Gastric Emptying | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Small Intestinal Obstruction | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Bile Duct Stone | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Hepatitis | Hepatobiliary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Skin Necrosis | Skin and subcutaneous tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Groin Pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Intervertebral Disc Degeneration | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Lumbar Spinal Stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Muscle Spasms | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Musculoskeletal Chest Pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Neck Pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Spinal Column Stenosis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Spinal Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Spondylolisthesis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Tenosynovitis | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Bladder Prolapse | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Renal Failure | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Renal Failure Acute | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Urinary Retention | Renal and urinary disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Sickle Cell Anaemia with Crisis | Congenital, familial and genetic disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Device Dislocation | General disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Non-Cardiac Chest Pain | General disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Surgical Failure | General disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Blood Potassium Increased | Investigations | MedDRA 16.0 | Systematic Assessment |
| |
| Accidental Overdose | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Lower Limb Fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Patella Fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Peripheral Artery Restenosis | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Post-Traumatic Neck Syndrome | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Postoperative Respiratory Failure | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Road Traffic Accident | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Traumatic Haematoma | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
| |
| Wrist Fracture | Injury, poisoning and procedural complications | MedDRA 16.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Upper Respiratory Tract Infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Urinary Tract Infection | Infections and infestations | MedDRA 16.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Abdominal Pain | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 16.0 | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA 16.0 | Systematic Assessment |
|
The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Shionogi Clinical Trials Administrator | Shionogi Inc. | 800-849-9707 | 1454 | shionogiclintrials-admin@shionogi.co.jp |
| ID | Term |
|---|---|
| D000079689 | Opioid-Induced Constipation |
| ID | Term |
|---|---|
| D003248 | Constipation |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000620491 | naldemedine |
Not provided
Not provided
Not provided
| ≥ 40 to < 65 years |
|
| ≥ 65 years |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Black or African American |
|
| Native Hawaiian or Other Pacific Islander |
|
| White |
|
| > 100 mg |
|
| AEs leading to discontinuation of study drug |
|
| Serious adverse events |
|
| Serious adverse drug reactions |
|
| SAEs leading to discontinuation of study drug |
|
| Deaths |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
| Participants |
|
|
|
| Participants |
|
|
|
|
|
|
|
|